Small Cell Transformation of EGFR-Mutant NSCLC Treated with Tyrosine Kinase Inhibition
Post-transformation somatic mutation testing and germline testing at presentation revealed unique mutational profiles not previously reported in the setting of HT to SCLC. Further investigations are required to determine the optimal treatment and sequencing following HT.
Authors
- Adam Rock (ORCID: https://orcid.org/0000-0002-5859-6965)
- Ravi Salgia (ORCID: https://orcid.org/0000-0001-9643-7626)
- Stacy W. Gray (ORCID: https://orcid.org/0000-0001-6948-0143)
- Isa Mambetsariev (ORCID: https://orcid.org/0000-0003-2882-0249)
- Siddhika Pareek (ORCID: https://orcid.org/0000-0003-2305-5322)
- W. Kareem
- Jeremy Fricke (ORCID: https://orcid.org/0000-0003-4684-8114)
- Leonidas Arvanitis (ORCID: https://orcid.org/0000-0002-4744-8350)
- Xiaochen Li (ORCID: https://orcid.org/0009-0002-9602-7795)
- Débora S. Bruno
- Javier Arias-Romero (ORCID: https://orcid.org/0009-0006-7629-7156)
Institutions
- City of Hope (US)
Publication Details
- Journal
- Current Oncology
- Published
- 2025-10-03
- DOI
- https://doi.org/10.3390/curroncol32100554
- Citations
- 2
- Primary Topic
- Lung Cancer Treatments and Mutations
- Type
- article
- Field-Weighted Citation Impact
- 3.04